SynthesisAnnals of medicine2025
Prognostic value of C-reactive protein in patients with melanoma: a meta-analysis.
Synthesis in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Value of the Vitamin B12/C-Reactive Protein Index in Resected Stage II-III Cutaneous Melanoma: Comparison with Its Individual Components.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundC-reactive protein (CRP) has been widely investigated for its prognostic value for melanoma, however, findings remained different. Consequently, this meta-analysis was performed for identifying its precise role in forecasting melanoma prognosis.
methodsWe searched PubMed, Web of Science, Embase and Cochrane Library till 25 January 2025, and computed combined hazard ratios (HRs) and 95% confidence intervals (CIs) for estimating CRP's effect on forecasting overall survival (OS) and progression-free survival (PFS) of melanoma.
resultsNineteen studies consisting of 4634 cases were enrolled into the present work. As suggested by our data, higher CRP showed remarkable relation to dismal OS (HR = 2.26, 95% CI = 1.89-2.71,
conclusionHigh CRP remarkably predicts dismal OS and PFS of melanoma cases, which is the promising biomarker used to forecast melanoma prognosis in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.